[go: up one dir, main page]

MX2016011729A - Composicion y metodo de liberacion prolongada. - Google Patents

Composicion y metodo de liberacion prolongada.

Info

Publication number
MX2016011729A
MX2016011729A MX2016011729A MX2016011729A MX2016011729A MX 2016011729 A MX2016011729 A MX 2016011729A MX 2016011729 A MX2016011729 A MX 2016011729A MX 2016011729 A MX2016011729 A MX 2016011729A MX 2016011729 A MX2016011729 A MX 2016011729A
Authority
MX
Mexico
Prior art keywords
composition
dosage form
controlled release
coalescing agent
prolonged release
Prior art date
Application number
MX2016011729A
Other languages
English (en)
Other versions
MX383738B (es
Inventor
S Yang Hui
Ma Hua
Stokes Kevin
Original Assignee
Fmc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Corp filed Critical Fmc Corp
Publication of MX2016011729A publication Critical patent/MX2016011729A/es
Publication of MX383738B publication Critical patent/MX383738B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En un aspecto la presente invención se dirige a un método para realizar una forma de dosificación sólida de liberación controlada que tiene una capa de recubrimiento de etilcelulosa, esa capa comprende un agente de coalescencia que es un éster orgánico que tiene un valor HLB de 3 a 8. El uso de ese agente de coalescencia permite la formación de un recubrimiento de liberación controlada efectivo sin la necesidad de una etapa posterior de curado después del proceso de recubrimiento. En otros aspectos, esta invención se refiere a una dispersión acuosa útil en tal método; así como la forma de dosificación recubierta producida.
MX2016011729A 2014-03-11 2015-03-04 Composición y método de liberación prolongada. MX383738B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951065P 2014-03-11 2014-03-11
US201462073365P 2014-10-31 2014-10-31
PCT/US2015/018743 WO2015138200A1 (en) 2014-03-11 2015-03-04 Controlled release composition and method

Publications (2)

Publication Number Publication Date
MX2016011729A true MX2016011729A (es) 2016-10-28
MX383738B MX383738B (es) 2025-03-14

Family

ID=54067754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011729A MX383738B (es) 2014-03-11 2015-03-04 Composición y método de liberación prolongada.

Country Status (8)

Country Link
US (4) US20150258033A1 (es)
EP (1) EP3116483B1 (es)
JP (1) JP6616780B2 (es)
CN (1) CN106102723B (es)
BR (1) BR112016020738B1 (es)
CA (1) CA2940684C (es)
MX (1) MX383738B (es)
WO (1) WO2015138200A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
KR102113261B1 (ko) 2018-03-28 2020-05-20 주식회사 엘지화학 용출 제어형 비료

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330338A (en) * 1978-10-02 1982-05-18 Purdue Research Foundation Pharmaceutical coating composition, and preparation and dosages so coated
US4629753A (en) 1981-11-18 1986-12-16 The Lubrizol Corporation Water dispersed rust inhibitive coating compositions
IE59720B1 (en) * 1986-08-11 1994-03-23 Innovata Biomed Ltd Pharmaceutical formulations comprising microcapsules
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5853740A (en) * 1996-08-07 1998-12-29 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils
US5695551A (en) * 1996-12-09 1997-12-09 Dow Corning Corporation Water repellent composition
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1496091A1 (en) * 2003-07-08 2005-01-12 Rohm And Haas Company Aqueous polymer composition
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
RU2442574C2 (ru) * 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
US8088414B2 (en) * 2006-02-07 2012-01-03 Fmc Corporation Latex or pseudolatex compositions, coatings and coating processes
US7829148B2 (en) 2006-02-07 2010-11-09 Fmc Corporation Coating process to produce controlled release coatings
WO2010060008A1 (en) 2008-11-21 2010-05-27 Elementis Specialties, Inc. Voc-free coalescing agent
CN101919803A (zh) * 2010-07-16 2010-12-22 钟术光 一种控释制剂
EP2618803B1 (en) * 2010-09-20 2016-04-06 L'Oréal Aqueous cosmetic composition comprising alkylcellulose

Also Published As

Publication number Publication date
CA2940684C (en) 2023-05-02
EP3116483B1 (en) 2021-04-21
US20230072225A1 (en) 2023-03-09
US20180360763A1 (en) 2018-12-20
CN106102723A (zh) 2016-11-09
WO2015138200A1 (en) 2015-09-17
BR112016020738B1 (pt) 2023-04-11
CN106102723B (zh) 2021-06-25
JP2017507164A (ja) 2017-03-16
EP3116483A1 (en) 2017-01-18
MX383738B (es) 2025-03-14
US20150258033A1 (en) 2015-09-17
US20250312284A1 (en) 2025-10-09
JP6616780B2 (ja) 2019-12-04
CA2940684A1 (en) 2015-09-17
EP3116483A4 (en) 2017-11-08
BR112016020738A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
BR112017007864A2 (pt) método e sistema de tratamento de uma formação subterrânea, sistema para realizar um método, composição de peso aumentado, e, método de preparo de uma composição de peso aumentado.
CL2016002996A1 (es) Método para fabricar un material con superficie modificada que comprende: proporcionar un substrato, que comprende un compuesto alcalino salificable o alcalinotérreo; y aplicar una composición de tratamiento líquida que comprende un ácido; material con superficie modificada; y uso del material
CO2018003542A2 (es) Anticuerpo anti-garp
BR112016029241A2 (pt) método para tratamento dos cabelos com um condicionador concentrado
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
MX2016010051A (es) Composicion y metodo para ayudar a dormir.
BR112018075027A2 (pt) métodos de fabricação de aplicadores de precisão
BR112016027794A2 (pt) Composição de material de revestimento, método para produzir um revestimento multicamada, uso de uma composição de material de revestimento e substrato
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX388845B (es) Uso de pridopidina para tratar el sindrome de rett.
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
MX387410B (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico
BR112018000807A2 (pt) composição, utilização de 40 a 70% em peso de sabão, método para a deposição de um agente de benefícios e processo para a preparação da composição
CR20220112A (es) Composiciones que comprenden tigolaner para el control de parásitos
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
AR104710A1 (es) Método para producir un recubrimiento multicapa
MX2019003987A (es) Estructuras fibrosas que comprenden compuestos de agave volatiles.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih
AR102376A1 (es) Método de tratamiento para anti-brote de tubérculos con cantidad reducida de cipc
MX2016011729A (es) Composicion y metodo de liberacion prolongada.
ECSP17021465A (es) Formulación que comprende glicopirrolato, método y aparato